Bristol Myers reports promising preliminary results for its next-gen CAR T therapy CC-97540, showing safety and early efficacy in a Phase 1 study for severe autoimmune diseases.

We recently compiled a list of the 10 Best Immunotherapy Stocks to Buy Now. In this article, we are going to take a look at ...

Companies in the Healthcare sector have received a lot of coverage today as analysts weigh in on Bristol-Myers Squibb (BMY – Research Report) ...

Daiwa America upgraded shares of Bristol-Myers Squibb (NYSE:BMY – Free Report) from a hold rating to a strong-buy rating in a ...

Fintel reports that on November 15, 2024, Wolfe Research initiated coverage of Bristol-Myers Squibb (NYSE:BMY) with a Peer ...

Bristol Myers Squibb (BMY) has received a recommendation for approval from an expert panel of the European Medicines Agency ...

Top 15. In this article, we are going to take a look at where Bristol-Myers Squibb Company (NYSE:BMY) stands against the ...

On Tuesday, Bristol-Myers Squibb Co (BMY) stock saw a decline, ending the day at $59.02 which represents a decrease of $-0.80 or -1.34% from the prior close of $59.82. The stock opened at $59.82 and ...

Leerink upgrades Bristol-Myers Squibb with an increased price target and strong sales projections for Cobenfy and milvexian, ...

Morgan Stanley raised the firm’s price target on Bristol Myers (BMY) to $39 from $36 and keeps an Underweight rating on the shares ...

AbbVie Inc.'s disappointing trial results for its new schizophrenia drug bode well for rival Bristol Myers Squibb Co., analysts said.

Bristol-Myers Squibb (BMY) stock was upgraded by Leerink Partners based on a potential sales boost for its schizophrenia ...